Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON



15 November 2022, 07:00 am CET

Data from SAHARA with first-generation DSR product (DSR 1.0) confirm:
Safe, effective and rapid elimination of persistent congestion following intensive DSR therapy
Considerable benefit in cardio-renal status maintained till end of study (16 weeks post-intensive DSR therapy)
Dramatic and sustained improvement in diuretic response up to 15 months post intensive DSR therapy
No congestion-related heart failure re-hospitalizations during entire study
One class improvement of NYHA status and 75% reduction in predicted one-year mortality based on Seattle Heart Failure model
First patient dosed successfully in YUKON, Ph. 1 study of second-generation DSR product (DSR 2.0)
MOJAVE, US Ph. 1/2a randomized controlled multi-center study of DSR 2.0, on track to start in H1 2023
Company presentation with webcast at Jefferies Healthcare Conference on 17 November 2022

Read more here.